Journal
BIOMARKER RESEARCH
Volume 8, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40364-020-00196-2
Keywords
Targeted therapy; Gene mutation; Acute myeloid leukemia (AML)
Categories
Funding
- Key Scientific Research Project of Henan Provincial Education Department [20A320062, 19A320046]
- National Natural Science Foundation of China [U1804192]
- Special Talents Project Fund of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Ask authors/readers for more resources
Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mortality rate in the past few decades, long term overall survival has stagnated. Exciting developments of gene mutation-targeted therapeutic agents are now changing the landscape in AML treatment. New agents offer more clinical options for patients and also confer a more promising outcome. Since Midostaurin, a FLT3 inhibitor, was first approved by US FDA in 2017 as the first gene mutation-targeted therapeutic agent, an array of new gene mutation-targeted agents are now available for AML treatment. In this review, we will summarize the recent advances in gene mutation-targeted therapies for patients with AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available